Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

OXCARBAZEPINE

All products: not a benefit

Other products in the same Health Canada class (N03A, N03AF) — coverage varies; not interchangeable

  • Carbamazepine (Tegretol): general benefit, Limited Use, Not a benefit, Listing status unconfirmed
  • Eslicarbazepine (Aptiom): limited Use 430
  • Rufinamide (Banzel): not a benefit
  • Clonazepam (Rivotril): general benefit
  • Divalproex (Epival): general benefit
  • Ethosuximide (Zarontin): general benefit

14 more in the class list below

Apo-Oxcarbazepine · DIN 02284294 · 150mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Trileptal; DOSAGE FORM/ STRENGTH: 150 mg, 300 mg, and 600 mg tablet 60 mg/mL — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Oxcarbazepine Brand(s): Trileptal DOSAGE FORM/ STRENGTH: 150 mg, 300 mg, and 600 mg tablet 60 mg/mL For the treatment of partial seizures in adults and in children aged 6 years and older who have had an inadequate response or intolerance* to at least 3 other formulary agents (prior or current use) including carbamazepine. * Intolerance must be described in detail. Warning: Life-threatening dermatological reactions, including Stevens Johnson Syndrome and toxic epidermal necrolysis, and multi-organ hypersensitivity reactions have been associated with the use of oxcarbazepine. More information may be found on the Health Canada webpage: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/trileptal_hpc-cps_e.html Duration of Approval: Lifetime 31 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 31, record 12, corpus 2025-01-01; name match only, not an eligibility decision
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Oxcarbazepine · DIN 02284294 Manufacturer: Apotex Inc.; listing date 2008-06-27 Health Canada: Marketed since 2022-02-08 · brand APO-OXCARBAZEPINE · ATC N03AF02 OXCARBAZEPINE · form Tablet · route Oral · ingredients OXCARBAZEPINE 150 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Oxcarbazepine: Formulary list price $0.6209/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6209 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76987 · Verify on the e-Formulary ↗ (DIN 02284294)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02284294). DIN 02284294: Apo-Oxcarbazepine Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 281200087; group id 436; item number 1087; lccId None; manufacturer id APX Source form: Tab; strength: 150mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.6209; ministry $0.6209 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02284294 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76987
Interchangeable products
Jamp Oxcarbazepine · DIN 02560593 · $0.6209 Jamp-Oxcarbazepine · DIN 02440717 · $0.6210 Trileptal · DIN 02242067 · not recorded
Shortage status: active shortage (reported 2026-08-18, estimated to end 2026-10-18, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02284294
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Oxcarbazepine · DIN 02560593 · 150mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Trileptal; DOSAGE FORM/ STRENGTH: 150 mg, 300 mg, and 600 mg tablet 60 mg/mL — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Oxcarbazepine Brand(s): Trileptal DOSAGE FORM/ STRENGTH: 150 mg, 300 mg, and 600 mg tablet 60 mg/mL For the treatment of partial seizures in adults and in children aged 6 years and older who have had an inadequate response or intolerance* to at least 3 other formulary agents (prior or current use) including carbamazepine. * Intolerance must be described in detail. Warning: Life-threatening dermatological reactions, including Stevens Johnson Syndrome and toxic epidermal necrolysis, and multi-organ hypersensitivity reactions have been associated with the use of oxcarbazepine. More information may be found on the Health Canada webpage: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/trileptal_hpc-cps_e.html Duration of Approval: Lifetime 31 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 31, record 12, corpus 2025-01-01; name match only, not an eligibility decision
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Oxcarbazepine · DIN 02560593 Manufacturer: Jamp Pharma Corporation; listing date 2026-08-31 Health Canada: Marketed since 2026-07-24 · brand JAMP OXCARBAZEPINE · ATC N03AF02 OXCARBAZEPINE · form Tablet · route Oral · ingredients OXCARBAZEPINE 150 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Oxcarbazepine: Formulary list price $0.6209/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6209 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106364 · Verify on the e-Formulary ↗ (DIN 02560593)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02560593). DIN 02560593: Jamp Oxcarbazepine Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 281200087; group id 436; item number 1087; lccId None; manufacturer id JPC Source form: Tab; strength: 150mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.6209; ministry $0.6209 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02560593 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106364
Interchangeable products
Apo-Oxcarbazepine · DIN 02284294 · $0.6209 Jamp-Oxcarbazepine · DIN 02440717 · $0.6210 Trileptal · DIN 02242067 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02560593
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Oxcarbazepine · DIN 02284308 · 300mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Trileptal; DOSAGE FORM/ STRENGTH: 150 mg, 300 mg, and 600 mg tablet 60 mg/mL — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Oxcarbazepine Brand(s): Trileptal DOSAGE FORM/ STRENGTH: 150 mg, 300 mg, and 600 mg tablet 60 mg/mL For the treatment of partial seizures in adults and in children aged 6 years and older who have had an inadequate response or intolerance* to at least 3 other formulary agents (prior or current use) including carbamazepine. * Intolerance must be described in detail. Warning: Life-threatening dermatological reactions, including Stevens Johnson Syndrome and toxic epidermal necrolysis, and multi-organ hypersensitivity reactions have been associated with the use of oxcarbazepine. More information may be found on the Health Canada webpage: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/trileptal_hpc-cps_e.html Duration of Approval: Lifetime 31 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 31, record 12, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Apo-Oxcarbazepine · DIN 02284308 Manufacturer: Apotex Inc.; listing date 2008-06-27 Health Canada: Marketed since 2016-06-08 · brand APO-OXCARBAZEPINE · ATC N03AF02 OXCARBAZEPINE · form Tablet · route Oral · ingredients OXCARBAZEPINE 300 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Oxcarbazepine: Formulary list price $0.9102/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9102 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76988 · Verify on the e-Formulary ↗ (DIN 02284308)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02284308). DIN 02284308: Apo-Oxcarbazepine Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 281200088; group id 436; item number 1088; lccId None; manufacturer id APX Source form: Tab; strength: 300mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.9102; ministry $0.9102 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02284308 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76988
Interchangeable products
Jamp Oxcarbazepine · DIN 02560607 · $0.9102 Jamp-Oxcarbazepine · DIN 02440725 · $0.9102 Trileptal · DIN 02242068 · not recorded
Shortage status: active shortage (reported 2026-08-25, estimated to end 2026-10-18, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02284308
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Oxcarbazepine · DIN 02560607 · 300mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Trileptal; DOSAGE FORM/ STRENGTH: 150 mg, 300 mg, and 600 mg tablet 60 mg/mL — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Oxcarbazepine Brand(s): Trileptal DOSAGE FORM/ STRENGTH: 150 mg, 300 mg, and 600 mg tablet 60 mg/mL For the treatment of partial seizures in adults and in children aged 6 years and older who have had an inadequate response or intolerance* to at least 3 other formulary agents (prior or current use) including carbamazepine. * Intolerance must be described in detail. Warning: Life-threatening dermatological reactions, including Stevens Johnson Syndrome and toxic epidermal necrolysis, and multi-organ hypersensitivity reactions have been associated with the use of oxcarbazepine. More information may be found on the Health Canada webpage: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/trileptal_hpc-cps_e.html Duration of Approval: Lifetime 31 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 31, record 12, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Jamp Oxcarbazepine · DIN 02560607 Manufacturer: Jamp Pharma Corporation; listing date 2026-08-31 Health Canada: Marketed since 2026-07-24 · brand JAMP OXCARBAZEPINE · ATC N03AF02 OXCARBAZEPINE · form Tablet · route Oral · ingredients OXCARBAZEPINE 300 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Oxcarbazepine: Formulary list price $0.9102/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9102 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106365 · Verify on the e-Formulary ↗ (DIN 02560607)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02560607). DIN 02560607: Jamp Oxcarbazepine Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 281200088; group id 436; item number 1088; lccId None; manufacturer id JPC Source form: Tab; strength: 300mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.9102; ministry $0.9102 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02560607 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106365
Interchangeable products
Apo-Oxcarbazepine · DIN 02284308 · $0.9102 Jamp-Oxcarbazepine · DIN 02440725 · $0.9102 Trileptal · DIN 02242068 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02560607
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Trileptal · DIN 02242068 · 300mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Oxcarbazepine Brand(s): Trileptal DOSAGE FORM/ STRENGTH: 150 mg, 300 mg, and 600 mg tablet 60 mg/mL For the treatment of partial seizures in adults and in children aged 6 years and older who have had an inadequate response or intolerance* to at least 3 other formulary agents (prior or current use) including carbamazepine. * Intolerance must be described in detail. Warning: Life-threatening dermatological reactions, including Stevens Johnson Syndrome and toxic epidermal necrolysis, and multi-organ hypersensitivity reactions have been associated with the use of oxcarbazepine. More information may be found on the Health Canada webpage: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/trileptal_hpc-cps_e.html Duration of Approval: Lifetime 31 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 31, record 12, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)
1 brand, same coverage
Trileptal · DIN 02242068 Manufacturer: Novartis Pharma Canada Inc.; listing date 2008-06-27 Health Canada: Marketed since 2002-04-01 · brand TRILEPTAL 300 MG · ATC N03AF02 OXCARBAZEPINE · form Tablet · route Oral · ingredients OXCARBAZEPINE 300 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Trileptal: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65741 · Verify on the e-Formulary ↗ (DIN 02242068)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02242068). DIN 02242068: Trileptal Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 281200088; group id 436; item number 1088; lccId None; manufacturer id NOV Source form: Tab; strength: 300mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242068 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65741
Interchangeable products
Apo-Oxcarbazepine · DIN 02284308 · $0.9102 Jamp Oxcarbazepine · DIN 02560607 · $0.9102 Jamp-Oxcarbazepine · DIN 02440725 · $0.9102
Shortage status: resolved shortage (ended 2023-02-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242068
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Oxcarbazepine · DIN 02284316 · 600mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Trileptal; DOSAGE FORM/ STRENGTH: 150 mg, 300 mg, and 600 mg tablet 60 mg/mL — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Oxcarbazepine Brand(s): Trileptal DOSAGE FORM/ STRENGTH: 150 mg, 300 mg, and 600 mg tablet 60 mg/mL For the treatment of partial seizures in adults and in children aged 6 years and older who have had an inadequate response or intolerance* to at least 3 other formulary agents (prior or current use) including carbamazepine. * Intolerance must be described in detail. Warning: Life-threatening dermatological reactions, including Stevens Johnson Syndrome and toxic epidermal necrolysis, and multi-organ hypersensitivity reactions have been associated with the use of oxcarbazepine. More information may be found on the Health Canada webpage: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/trileptal_hpc-cps_e.html Duration of Approval: Lifetime 31 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 31, record 12, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Apo-Oxcarbazepine · DIN 02284316 Manufacturer: Apotex Inc.; listing date 2008-06-27 Health Canada: Marketed since 2016-06-08 · brand APO-OXCARBAZEPINE · ATC N03AF02 OXCARBAZEPINE · form Tablet · route Oral · ingredients OXCARBAZEPINE 600 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Oxcarbazepine: Formulary list price $1.8204/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.8204 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76989 · Verify on the e-Formulary ↗ (DIN 02284316)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02284316). DIN 02284316: Apo-Oxcarbazepine Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 281200089; group id 436; item number 1089; lccId None; manufacturer id APX Source form: Tab; strength: 600mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $1.8204; ministry $1.8204 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02284316 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76989
Interchangeable products
Jamp Oxcarbazepine · DIN 02560615 · $1.8204 Jamp-Oxcarbazepine · DIN 02440733 · $1.8204 Trileptal · DIN 02242069 · not recorded
Shortage status: active shortage (reported 2026-08-25, estimated to end 2026-10-18, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02284316
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Oxcarbazepine · DIN 02560615 · 600mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Trileptal; DOSAGE FORM/ STRENGTH: 150 mg, 300 mg, and 600 mg tablet 60 mg/mL — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Oxcarbazepine Brand(s): Trileptal DOSAGE FORM/ STRENGTH: 150 mg, 300 mg, and 600 mg tablet 60 mg/mL For the treatment of partial seizures in adults and in children aged 6 years and older who have had an inadequate response or intolerance* to at least 3 other formulary agents (prior or current use) including carbamazepine. * Intolerance must be described in detail. Warning: Life-threatening dermatological reactions, including Stevens Johnson Syndrome and toxic epidermal necrolysis, and multi-organ hypersensitivity reactions have been associated with the use of oxcarbazepine. More information may be found on the Health Canada webpage: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/trileptal_hpc-cps_e.html Duration of Approval: Lifetime 31 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 31, record 12, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Jamp Oxcarbazepine · DIN 02560615 Manufacturer: Jamp Pharma Corporation; listing date 2026-08-31 Health Canada: Marketed since 2026-07-24 · brand JAMP OXCARBAZEPINE · ATC N03AF02 OXCARBAZEPINE · form Tablet · route Oral · ingredients OXCARBAZEPINE 600 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Oxcarbazepine: Formulary list price $1.8204/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.8204 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106366 · Verify on the e-Formulary ↗ (DIN 02560615)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02560615). DIN 02560615: Jamp Oxcarbazepine Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 281200089; group id 436; item number 1089; lccId None; manufacturer id JPC Source form: Tab; strength: 600mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $1.8204; ministry $1.8204 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02560615 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106366
Interchangeable products
Apo-Oxcarbazepine · DIN 02284316 · $1.8204 Jamp-Oxcarbazepine · DIN 02440733 · $1.8204 Trileptal · DIN 02242069 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02560615
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Trileptal · DIN 02242069 · 600mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Oxcarbazepine Brand(s): Trileptal DOSAGE FORM/ STRENGTH: 150 mg, 300 mg, and 600 mg tablet 60 mg/mL For the treatment of partial seizures in adults and in children aged 6 years and older who have had an inadequate response or intolerance* to at least 3 other formulary agents (prior or current use) including carbamazepine. * Intolerance must be described in detail. Warning: Life-threatening dermatological reactions, including Stevens Johnson Syndrome and toxic epidermal necrolysis, and multi-organ hypersensitivity reactions have been associated with the use of oxcarbazepine. More information may be found on the Health Canada webpage: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/trileptal_hpc-cps_e.html Duration of Approval: Lifetime 31 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 31, record 12, corpus 2025-01-01; name match only, not an eligibility decision
How long EAP takes
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)
1 brand, same coverage
Trileptal · DIN 02242069 Manufacturer: Novartis Pharma Canada Inc.; listing date 2008-06-27 Health Canada: Marketed since 2002-04-01 · brand TRILEPTAL 600 MG · ATC N03AF02 OXCARBAZEPINE · form Tablet · route Oral · ingredients OXCARBAZEPINE 600 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Trileptal: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65742 · Verify on the e-Formulary ↗ (DIN 02242069)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02242069). DIN 02242069: Trileptal Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 281200089; group id 436; item number 1089; lccId None; manufacturer id NOV Source form: Tab; strength: 600mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242069 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65742
Interchangeable products
Apo-Oxcarbazepine · DIN 02284316 · $1.8204 Jamp Oxcarbazepine · DIN 02560615 · $1.8204 Jamp-Oxcarbazepine · DIN 02440733 · $1.8204
Shortage status: resolved shortage (ended 2023-02-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242069
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Oxcarbazepine · DIN 02440717 · 150mg · tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2022-09-06 — choose a marketed DIN from the same-category list.Discontinued 2022-09-06 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2022-09-06 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2022-09-06 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Trileptal; DOSAGE FORM/ STRENGTH: 150 mg, 300 mg, and 600 mg tablet 60 mg/mL — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Oxcarbazepine Brand(s): Trileptal DOSAGE FORM/ STRENGTH: 150 mg, 300 mg, and 600 mg tablet 60 mg/mL For the treatment of partial seizures in adults and in children aged 6 years and older who have had an inadequate response or intolerance* to at least 3 other formulary agents (prior or current use) including carbamazepine. * Intolerance must be described in detail. Warning: Life-threatening dermatological reactions, including Stevens Johnson Syndrome and toxic epidermal necrolysis, and multi-organ hypersensitivity reactions have been associated with the use of oxcarbazepine. More information may be found on the Health Canada webpage: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/trileptal_hpc-cps_e.html Duration of Approval: Lifetime 31 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 31, record 12, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Jamp-Oxcarbazepine · DIN 02440717 Manufacturer: Jamp Pharma Corporation; listing date 2015-10-29 Health Canada: Cancelled post market since 2022-09-06 · brand JAMP-OXCARBAZEPINE · ATC N03AF02 OXCARBAZEPINE · form Tablet · route Oral · ingredients OXCARBAZEPINE 150 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp-Oxcarbazepine: Formulary list price $0.6210/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6210 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92508 · Verify on the e-Formulary ↗ (DIN 02440717)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02440717). DIN 02440717: Jamp-Oxcarbazepine Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 281200087; group id 436; item number 1087; lccId None; manufacturer id JPC Source form: Tab; strength: 150mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.6210; ministry $0.6210 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02440717 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92508
Interchangeable products
Apo-Oxcarbazepine · DIN 02284294 · $0.6209 Jamp Oxcarbazepine · DIN 02560593 · $0.6209 Trileptal · DIN 02242067 · not recorded
Shortage status: active shortage (reported 2018-10-12, estimated to end 2022-12-30, last updated 2021-04-07) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02440717
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2022-09-06 — choose a marketed DIN from the same-category list.

Trileptal · DIN 02242067 · 150mg · tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2019-10-10 — choose a marketed DIN from the same-category list.Discontinued 2019-10-10 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2019-10-10 — choose a marketed DIN from the same-category list.
Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗); Health Canada lists this DIN as Cancelled post market since 2019-10-10 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Oxcarbazepine Brand(s): Trileptal DOSAGE FORM/ STRENGTH: 150 mg, 300 mg, and 600 mg tablet 60 mg/mL For the treatment of partial seizures in adults and in children aged 6 years and older who have had an inadequate response or intolerance* to at least 3 other formulary agents (prior or current use) including carbamazepine. * Intolerance must be described in detail. Warning: Life-threatening dermatological reactions, including Stevens Johnson Syndrome and toxic epidermal necrolysis, and multi-organ hypersensitivity reactions have been associated with the use of oxcarbazepine. More information may be found on the Health Canada webpage: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/trileptal_hpc-cps_e.html Duration of Approval: Lifetime 31 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 31, record 12, corpus 2025-01-01; name match only, not an eligibility decision
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
How long EAP takes
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)
1 brand, same coverage
Trileptal · DIN 02242067 Manufacturer: Novartis Pharma Canada Inc.; listing date 2008-06-27 Health Canada: Cancelled post market since 2019-10-10 · brand TRILEPTAL 150 MG · ATC N03AF02 OXCARBAZEPINE · form Tablet · route Oral · ingredients OXCARBAZEPINE 150 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Trileptal: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65740 · Verify on the e-Formulary ↗ (DIN 02242067)

Source record
DIN 02242067: Trileptal Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 281200087; group id 436; item number 1087; lccId None; manufacturer id NOV Source form: Tab; strength: 150mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242067 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65740
Interchangeable products
Apo-Oxcarbazepine · DIN 02284294 · $0.6209 Jamp Oxcarbazepine · DIN 02560593 · $0.6209 Jamp-Oxcarbazepine · DIN 02440717 · $0.6210
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242067
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2019-10-10 — choose a marketed DIN from the same-category list.

Jamp-Oxcarbazepine · DIN 02440725 · 300mg · tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2022-09-06 — choose a marketed DIN from the same-category list.Discontinued 2022-09-06 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2022-09-06 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2022-09-06 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Trileptal; DOSAGE FORM/ STRENGTH: 150 mg, 300 mg, and 600 mg tablet 60 mg/mL — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Oxcarbazepine Brand(s): Trileptal DOSAGE FORM/ STRENGTH: 150 mg, 300 mg, and 600 mg tablet 60 mg/mL For the treatment of partial seizures in adults and in children aged 6 years and older who have had an inadequate response or intolerance* to at least 3 other formulary agents (prior or current use) including carbamazepine. * Intolerance must be described in detail. Warning: Life-threatening dermatological reactions, including Stevens Johnson Syndrome and toxic epidermal necrolysis, and multi-organ hypersensitivity reactions have been associated with the use of oxcarbazepine. More information may be found on the Health Canada webpage: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/trileptal_hpc-cps_e.html Duration of Approval: Lifetime 31 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 31, record 12, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Jamp-Oxcarbazepine · DIN 02440725 Manufacturer: Jamp Pharma Corporation; listing date 2015-10-29 Health Canada: Cancelled post market since 2022-09-06 · brand JAMP-OXCARBAZEPINE · ATC N03AF02 OXCARBAZEPINE · form Tablet · route Oral · ingredients OXCARBAZEPINE 300 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp-Oxcarbazepine: Formulary list price $0.9102/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9102 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92509 · Verify on the e-Formulary ↗ (DIN 02440725)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02440725). DIN 02440725: Jamp-Oxcarbazepine Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 281200088; group id 436; item number 1088; lccId None; manufacturer id JPC Source form: Tab; strength: 300mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.9102; ministry $0.9102 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02440725 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92509
Interchangeable products
Apo-Oxcarbazepine · DIN 02284308 · $0.9102 Jamp Oxcarbazepine · DIN 02560607 · $0.9102 Trileptal · DIN 02242068 · not recorded
Shortage status: active shortage (reported 2018-10-12, estimated to end 2022-12-30, last updated 2021-04-07) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02440725
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2022-09-06 — choose a marketed DIN from the same-category list.

Jamp-Oxcarbazepine · DIN 02440733 · 600mg · tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2022-09-06 — choose a marketed DIN from the same-category list.Discontinued 2022-09-06 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2022-09-06 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2022-09-06 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria
Exceptional Access criteria on record are for Brand(s): Trileptal; DOSAGE FORM/ STRENGTH: 150 mg, 300 mg, and 600 mg tablet 60 mg/mL — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Oxcarbazepine Brand(s): Trileptal DOSAGE FORM/ STRENGTH: 150 mg, 300 mg, and 600 mg tablet 60 mg/mL For the treatment of partial seizures in adults and in children aged 6 years and older who have had an inadequate response or intolerance* to at least 3 other formulary agents (prior or current use) including carbamazepine. * Intolerance must be described in detail. Warning: Life-threatening dermatological reactions, including Stevens Johnson Syndrome and toxic epidermal necrolysis, and multi-organ hypersensitivity reactions have been associated with the use of oxcarbazepine. More information may be found on the Health Canada webpage: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/trileptal_hpc-cps_e.html Duration of Approval: Lifetime 31 EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 31, record 12, corpus 2025-01-01; name match only, not an eligibility decision
1 brand, same coverage
Jamp-Oxcarbazepine · DIN 02440733 Manufacturer: Jamp Pharma Corporation; listing date 2015-10-29 Health Canada: Cancelled post market since 2022-09-06 · brand JAMP-OXCARBAZEPINE · ATC N03AF02 OXCARBAZEPINE · form Tablet · route Oral · ingredients OXCARBAZEPINE 600 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp-Oxcarbazepine: Formulary list price $1.8204/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.8204 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92510 · Verify on the e-Formulary ↗ (DIN 02440733)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02440733). DIN 02440733: Jamp-Oxcarbazepine Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 281200089; group id 436; item number 1089; lccId None; manufacturer id JPC Source form: Tab; strength: 600mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $1.8204; ministry $1.8204 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02440733 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92510
Interchangeable products
Apo-Oxcarbazepine · DIN 02284316 · $1.8204 Jamp Oxcarbazepine · DIN 02560615 · $1.8204 Trileptal · DIN 02242069 · not recorded
Shortage status: active shortage (reported 2018-10-12, estimated to end 2022-12-30, last updated 2021-04-07) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02440733
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2022-09-06 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:12 Anticonvulsants) and how they are covered

Matched class: 28:12 Anticonvulsants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CLONAZEPAM, DIVALPROEX SODIUM, ETHOSUXIMIDE, LAMOTRIGINE, VALPROATE SODIUM Some products covered without a code (check the product listing): CARBAMAZEPINE, GABAPENTIN, PHENYTOIN (DIPHENYLHYDANTOIN), PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM, PREGABALIN, PRIMIDONE, TOPIRAMATE, VALPROIC ACID 28:12 Anticonvulsants

CARBAMAZEPINE

· 15 products · Listed, not a benefit (3), General benefit (6), Temporary benefit (2), Limited Use, codes 67 (4) · strengths: 100mg, 200mg, 400mg, 100mg/5mL · Chew Tab, ER Tab, LA Tab, Oral Susp, Tab

ESLICARBAZEPINE ACETATE

· 12 products · Limited Use, codes 430 · strengths: 200mg, 400mg, 600mg, 800mg · Tab

RUFINAMIDE

· 4 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 200mg, 400mg · Tab

CLONAZEPAM

· 9 products · General benefit · strengths: 0.5mg, 2mg · Tab

DIVALPROEX SODIUM

· 9 products · General benefit · strengths: 125mg, 250mg, 500mg · Ent Tab

ETHOSUXIMIDE

· 4 products · General benefit · strengths: 250mg, 50mg/mL · Cap, O/L

LAMOTRIGINE

· 28 products · General benefit · strengths: 25mg, 100mg, 150mg · Tab

PHENYTOIN (DIPHENYLHYDANTOIN)

· 4 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (2) · strengths: 6mg/mL, 25mg/mL, 50mg · O/L, Tab

PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM

· 4 products · General benefit (3), Limited Use, codes 481, 657 (1) · strengths: 30mg, 100mg, 50mg/mL · Cap, Inj Sol (Preservative Free)

PRIMIDONE

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 125mg, 250mg · Tab

TOPIRAMATE

· 54 products · Limited Use, codes 321 (2), Off-Formulary Interchangeable, not an ODB benefit (3), General benefit (49) · strengths: 15mg, 25mg, 50mg, 100mg, 200mg · Sprinkle Cap, Tab

VALPROATE SODIUM

· 5 products · General benefit · strengths: 50mg/mL · O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:12 and 11 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications TRILEPTAL (oxcarbazepine) is indicated for: • use as monotherapy or adjunctive therapy in the treatment of partial seizures. 1.1. Pediatrics Pediatrics (6 to 16 years of age): TRILEPTAL is indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures. 1.2. Geriatrics Geriatrics (> 65 years of age): Evidence from clinical studies indicates that there are differences in the pharmacokinetic profile of oxcarbazepine in the geriatric population relative to younger adults, which may be associated with differences in safety or effectiveness. A brief discussion can be found in the appropriate sections (See 7.1.4 Geriatrics; 10.3 Pharmacokinetics, Special Populations and Conditions; 4.1 Dosing Considerations). https://pdf.hres.ca/dpd_pm/00080945.PDF PM date: 2025-07-02 Source product: TRILEPTAL 300 MG; DIN 02242068; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Oxcarbazepine · DIN 02284294 Shortage status: active shortage (reported 2026-08-18, estimated to end 2026-10-18, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02284294

Check this DIN again

Apo-Oxcarbazepine · DIN 02284308 Shortage status: active shortage (reported 2026-08-25, estimated to end 2026-10-18, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02284308

Check this DIN again

Apo-Oxcarbazepine · DIN 02284316 Shortage status: active shortage (reported 2026-08-25, estimated to end 2026-10-18, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02284316

Check this DIN again

Jamp-Oxcarbazepine · DIN 02440717 Shortage status: active shortage (reported 2018-10-12, estimated to end 2022-12-30, last updated 2021-04-07) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02440717

Check this DIN again

Jamp-Oxcarbazepine · DIN 02440725 Shortage status: active shortage (reported 2018-10-12, estimated to end 2022-12-30, last updated 2021-04-07) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02440725

Check this DIN again

Jamp-Oxcarbazepine · DIN 02440733 Shortage status: active shortage (reported 2018-10-12, estimated to end 2022-12-30, last updated 2021-04-07) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02440733

Check this DIN again

Prepare an Exceptional Access request

SADIE has its own form for many drugs; this checklist prepares the answers; the ministry decides. Open SADIE

Use this text in SADIE’s free-text fields or read from it on a Telephone Request Service call. Review marks do not indicate eligibility. Evidence stays in this page until you copy it; nothing entered here is sent or saved. Do not enter patient identifiers.

EAP Telephone Request Service: The TRS can be accessed by calling toll-free at 1-866-811-9893 or 416-327-8109 (Toronto area) between 8:30 a.m. and 5:00 p.m. Monday through Friday (except holidays) and selecting the TRS option. Source; updated September 15, 2026

EAP fax: In Ontario: 1-866-811-9908 or 416-327-7526 (Toronto area). Outside Ontario: 1-833-905-4260. Source; updated September 15, 2026

Posted turnaround and Telephone Request Service scope
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
Source; updated September 15, 2026

Oxcarbazepine (Trileptal)

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Prepare answers: For the treatment of partial seizures in adults and in children aged 6 years and older who have had an inadequate response or intolerance* to at least 3 other formulary agents (prior or current use) including carbamazepine.

Ministry criteria corpus 2025-01-01; page 31

Oxcarbazepine Brand(s): Trileptal DOSAGE FORM/ STRENGTH: 150 mg, 300 mg, and 600 mg tablet 60 mg/mL
For the treatment of partial seizures in adults and in children aged 6 years and older who have had an inadequate response or intolerance* to at least 3 other formulary agents (prior or current use) including carbamazepine.
* Intolerance must be described in detail.
Warning: Life-threatening dermatological reactions, including Stevens Johnson Syndrome and toxic epidermal necrolysis, and multi-organ hypersensitivity reactions have been associated with the use of oxcarbazepine. More information may be found on the Health Canada webpage: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/trileptal_hpc-cps_e.html
Duration of Approval: Lifetime
31

Prepared from the ministry's published criteria; eligibility is decided by the Exceptional Access Program.

Other review policies

For Apo-Oxcarbazepine, Jamp Oxcarbazepine, Jamp-Oxcarbazepine: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026